Enhancing Digital Health Capabilities Through Integrated Blended Learning Approaches Across many low- and middle-income countries, the promise of digital health transformation is often constrained by a persistent and complex reality: fragmented systems, overlapping digital tools, and increasing pressure on health…
Roche Launches State-of-the-Art Institute of Human Biology Facility to Advance Next-Generation Human Model Systems in Drug Discovery and Development Roche has officially inaugurated a new state-of-the-art research facility to serve as the home of its Institute of Human Biology (IHB),…
Biogen to Showcase Late-Breaking Phase 2 AMETHYST Data on Litifilimab in Cutaneous Lupus Erythematosus at the 2026 American Academy of Dermatology Annual Meeting Biogen Inc. has announced a series of upcoming scientific presentations at the prestigious American Academy of Dermatology…
Allergan Aesthetics Highlights Shifting Trends in Modern Aesthetic Care Through Global Survey and Enhanced Educational Initiatives Allergan Aesthetics, a division of AbbVie and a globally recognized leader in the field of medical aesthetics, has unveiled a comprehensive new body of…
Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus placebo when added to standard of care in adult patients…
Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Enhancing Economies of Scale from Development to Manufacturing and Direct Commercialization Celltrion announced today that it will immediately incorporate newly announced global regulatory updates aimed at streamlining biosimilar development into its…
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings Tempus AI, Inc. a technology company leading the adoption of AI to advance precision medicine, announced the publication of a new study in JCO Precision…
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…
TIXiMED Reports Promising Preclinical Results for Oral TIX100 in Preventing Weight Regain After GLP-1 Therapy TIXiMED a clinical-stage pharmaceutical company focused on developing innovative treatments for diabetes and metabolic diseases, has announced encouraging new preclinical findings for its investigational oral…
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Vertex Pharmaceuticals Incorporated today announced positive data from a pre-specified Week 36 interim…
Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis Pfizer Inc. today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its…